Seeking Alpha

Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports...

Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports its proposed trial to test repeat treatment cycles of its Xifaxan tablets for irritable bowel syndrome. (earlier)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)